Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland

V. Niinikoski, AM. Barkoff, J. Mertsola, J. Holubova, J. Masin, P. Sebo, Q. He

. 2025 ; 58 (-) : 127279. [pub] 20250517

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015329
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 40383080
DOI 10.1016/j.vaccine.2025.127279
Knihovny.cz E-zdroje

BACKGROUND: Bordetella pertussis isolates which do not express some of acellular pertussis vaccine (aPv) antigens, e.g. pertactin (PRN), have been increasingly reported in countries using aPvs. In Finland, primary pertussis vaccination with whole-cell vaccine was replaced by aPv containing pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 2005 and then by aPv containing PT, FHA, and PRN in 2009. We aimed to study alterations in the expression of FHA, PRN, and PT, three antigens included in aPvs and adenylate cyclase toxin (ACT) not included in current aPvs, among Finnish isolates collected during 1991-2020. METHODS: Of 904 isolates collected by the Finnish Reference Laboratory for Pertussis during 1991-2020, 302 were randomly included. An adapted, monoclonal antibody based, antigen expression ELISA, including the culture of B. pertussis in Stainer-Scholte medium, was performed to quantify the expression of ACT, FHA, PRN, and PT of each isolate. ACT activity was also measured for 16 isolates. Arbitrary units were used for comparing levels of each antigen expression of isolates grouped in every five years. FINDINGS: Following the implementation of aPv in 2005, B. pertussis isolates exhibited a 1.75-fold increase for FHA (p < 0.001) and a 1.5-fold increase for ACT (p < 0.0041) expression until 2020. No FHA or ACT deficient isolates were detected. As the number of PRN deficient isolates has significantly increased with the time, the amount of PRN produced by the positive isolates has also started to decrease, especially after the use of aPv containing PRN. During this period, fluctuations in PT expression were observed. INTERPRETATION: The study demonstrated that in response to aPv-induced selection pressure, different types of selection of B. pertussis has occurred. For FHA and ACT, a steady increase in their production is observed, whereas the frequency of PRN deficient isolates is increased with time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015329
003      
CZ-PrNML
005      
20250731090920.0
007      
ta
008      
250708e20250517ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2025.127279 $2 doi
035    __
$a (PubMed)40383080
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Niinikoski, Vili $u Finnish Reference Laboratory for Pertussis and Diphtheria, Institute of Biomedicine, University of Turku, Turku, Finland
245    10
$a Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland / $c V. Niinikoski, AM. Barkoff, J. Mertsola, J. Holubova, J. Masin, P. Sebo, Q. He
520    9_
$a BACKGROUND: Bordetella pertussis isolates which do not express some of acellular pertussis vaccine (aPv) antigens, e.g. pertactin (PRN), have been increasingly reported in countries using aPvs. In Finland, primary pertussis vaccination with whole-cell vaccine was replaced by aPv containing pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 2005 and then by aPv containing PT, FHA, and PRN in 2009. We aimed to study alterations in the expression of FHA, PRN, and PT, three antigens included in aPvs and adenylate cyclase toxin (ACT) not included in current aPvs, among Finnish isolates collected during 1991-2020. METHODS: Of 904 isolates collected by the Finnish Reference Laboratory for Pertussis during 1991-2020, 302 were randomly included. An adapted, monoclonal antibody based, antigen expression ELISA, including the culture of B. pertussis in Stainer-Scholte medium, was performed to quantify the expression of ACT, FHA, PRN, and PT of each isolate. ACT activity was also measured for 16 isolates. Arbitrary units were used for comparing levels of each antigen expression of isolates grouped in every five years. FINDINGS: Following the implementation of aPv in 2005, B. pertussis isolates exhibited a 1.75-fold increase for FHA (p < 0.001) and a 1.5-fold increase for ACT (p < 0.0041) expression until 2020. No FHA or ACT deficient isolates were detected. As the number of PRN deficient isolates has significantly increased with the time, the amount of PRN produced by the positive isolates has also started to decrease, especially after the use of aPv containing PRN. During this period, fluctuations in PT expression were observed. INTERPRETATION: The study demonstrated that in response to aPv-induced selection pressure, different types of selection of B. pertussis has occurred. For FHA and ACT, a steady increase in their production is observed, whereas the frequency of PRN deficient isolates is increased with time.
650    12
$a Bordetella pertussis $x imunologie $x izolace a purifikace $7 D001886
650    _2
$a lidé $7 D006801
650    12
$a pertusová vakcína $x imunologie $x aplikace a dávkování $7 D010567
650    12
$a pertuse $x prevence a kontrola $x imunologie $x mikrobiologie $7 D014917
650    12
$a antigeny bakteriální $x imunologie $7 D000942
650    _2
$a faktory virulence rodu Bordetella $x imunologie $7 D010566
650    _2
$a pertusový toxin $x imunologie $7 D037342
650    _2
$a acelulární vakcíny $x imunologie $7 D022282
650    _2
$a adenylátcyklasový toxin $x imunologie $7 D037361
650    _2
$a ELISA $7 D004797
650    _2
$a proteiny vnější bakteriální membrány $x imunologie $7 D001425
650    _2
$a bakteriální adheziny $7 D018829
651    _2
$a Finsko $7 D005387
655    _2
$a časopisecké články $7 D016428
700    1_
$a Barkoff, Alex-Mikael $u Finnish Reference Laboratory for Pertussis and Diphtheria, Institute of Biomedicine, University of Turku, Turku, Finland; InFLAMES flagship center, University of Turku, Finland
700    1_
$a Mertsola, Jussi $u Finnish Reference Laboratory for Pertussis and Diphtheria, Institute of Biomedicine, University of Turku, Turku, Finland; InFLAMES flagship center, University of Turku, Finland
700    1_
$a Holubova, Jana $u Laboratory of Molecular Biology of Bacterial Pathogens, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Masin, Jiri $u Laboratory of Molecular Biology of Bacterial Pathogens, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Sebo, Peter $u Laboratory of Molecular Biology of Bacterial Pathogens, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a He, Qiushui $u Finnish Reference Laboratory for Pertussis and Diphtheria, Institute of Biomedicine, University of Turku, Turku, Finland; InFLAMES flagship center, University of Turku, Finland. Electronic address: Qiushui.He@utu.fi
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 58 (20250517), s. 127279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40383080 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090915 $b ABA008
999    __
$a ok $b bmc $g 2366280 $s 1252454
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 58 $c - $d 127279 $e 20250517 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace